期刊文献+

缬沙坦抑制非对称二甲基精氨酸诱导的内皮细胞LOX-1的表达 被引量:1

Valsartan Inhibited the Effect of Asymmetric Dimethylarginine Induced LOX-1 Expression in Human Umbilical Vein Endothelial Cells
下载PDF
导出
摘要 目的研究缬沙坦对非对称二甲基精氨酸(ADMA)诱导的人脐静脉内皮细胞(HUVEC)凝集素样氧化型低密度脂蛋白受体1(LOX-1)mRNA和蛋白表达的影响,并探讨其机制。方法体外培养HUVEC,以不同浓度的缬沙坦和15μmol/L ADMA共同孵育24 h,DCFH-DA检测细胞内活性氧(ROS)生成量;RT-PCR测定NADPH氧化酶p22phox及LOX-1 mRNA的转录水平;酶联免疫吸附法检测细胞LOX-1蛋白的表达水平。结果与ADMA组相比,缬沙坦干预后细胞ROS水平显著下降(P<0.05),p22phox和LOX-1 mRNA转录水平及LOX-1蛋白的表达水平明显下调(P<0.05),并呈剂量依赖性。结论缬沙坦通过抑制p22phox的表达减少细胞内ROS水平,进而抑制ADMA诱导的内皮细胞LOX-1 mRNA转录和蛋白表达,这可能是其独立于降压作用的抗动脉粥样硬化作用的部分机制。 Aim To investigate the effects of valsartan on lectin-like oxidized low density lipoprotein receptor 1 ( LOX-1 ) expression induced by asymmetric dimethylarginine (ADMA) in cultured human umbilical vein endothelial ceils (HUVEC). Methods 15 μmol/L ADMA was added into the cultured HUVEC for 24 h, intracellular reactive oxygen species (ROS) generation was measured by DCFH-DA. NADPH p22phox subunit and LOX-1 mRNA transcription were detected by quantitative competitive reverse transcription-polymerase chain reaction (RT-PCR). LOX-1 protein ex- pression was detected by cell enzyme linked immunosorbent as'say (ELISA). Results Valsartan significantly decreased intracellular ROS generation, inhibited the transcription of p22phox, LOX-1 mRNA and LOX-1 protein expression compared with ADMA group (P 〈 0. 05 ), and this effect was in a dose-dependent manner. Conclusions Valsartan inhibited expression of LOX-1 induced by ADMA, involving in inhibiting the expression of p22phox through decreasing intracellular ROS generation. This may be part of the mechanism of its anti-atherosclerotic effect independent of anti-hypertensive effect.
出处 《中国动脉硬化杂志》 CAS CSCD 北大核心 2013年第6期513-517,共5页 Chinese Journal of Arteriosclerosis
关键词 非对称二甲基精氨酸 凝集素样氧化型低密度脂蛋白受体1 NADPH氧化酶 活性氧 缬沙坦 Asymmetric Dimethylarginine Lectin-Like Oxidized Low Density Lipoprotein Receptor 1 NADPH Oxidase Reactive Oxygen Species Valsartan
  • 相关文献

参考文献17

  • 1Julius S,Weber MA,Kjeldsen SE,et al. The valsartanantihypertensive long-term use evaluation( VALUE) trial:outcomes in patients receiving monotherapy [J]. Hyperten-tion,2006,48(3):385-391.
  • 2NAVIGATOR Study Group,McMuiTay JJ,Holman RR,etal. Effect of valsartan on the incidence of diabetes and car-diovascular events[J]. N Engl J Med,2010,362(16):1477490.
  • 3Dandona P,Kumar V,Aljada A,et al. Angiotensin H re-ceptor blocker valsartan suppresses reactive oxygen speciesgeneration in leukocytes,nuclear factor-kappa B,in mono-nuclear cells of normal subjects:evidence of an antiinflam-matory action [J]. J Clin Endocrinol Metab,2003,88(9):4 496-501.
  • 4Hussein O,Shneider J,Rosenblat M,et al. Valsartantherapy has additive anti-oxidative effect to that of fluvasta-tin therapy against low-density lipoprotein oxidation:stud-ies in hypercholesterolemic and hypertensive patients [J].J Cardiovasc Pharmacol,2012,40( 1 ):28-34.
  • 5Hasegawa K,Wakino S,Tatematsu S,et al. Role of asym-metric dimethylarginine in vascular injury in transgenicmice overexpressing dimethylarginie dimethylaminohydro-lase 2[J]. Circ Res,2007,101(2):e2-el0.
  • 6Suda O,Tsutsui M,Morishita T,et al. Asymmetric dime-thylarginine produces vascular lesions inendothelial nitricoxide synthase-deficient mice:involvement of renin-angio-tensin system and oxidative stress [J]. Arterioscler ThrombVase Biol,2004,24(9):1 682-688.
  • 7张磊,黄元伟,姚航平.血管紧张素II和缬沙坦对人脐静脉内皮细胞血凝素样氧化低密度脂蛋白受体表达的影响[J].中华心血管病杂志,2002,30(10):630-633. 被引量:8
  • 8Yang XY,Jiang HG,Hartmann WK,et al. Developmentof a quantitative antigen specific cell based ELISA for the7G7/ B6 monoclonal antibody directed toward IL-2Ra[J].J Immunol Meth,2003,277(1-2):87-100.
  • 9林令君,王晓俐,吕晓霞,张东善,张绪洪.葡萄糖和厄贝沙坦对单核巨噬细胞系凝集素样氧化型低密度脂蛋白受体表达的影响[J].中国动脉硬化杂志,2012,20(2):107-110. 被引量:2
  • 10陈修平,赵海誉,钟章锋,徐曾涛,王一涛.“氧化型低密度脂蛋白—凝集素样氧化型低密度脂蛋白受体1—活性氧”信号通路参与泡沫细胞的形成(英文)[J].中国动脉硬化杂志,2010,18(7):577-581. 被引量:7

二级参考文献15

  • 1CHEN Xiu-ping DU Guan-hua.Lectin-like oxidized low-density lipoprotein receptor-1:protein,ligands,expression and pathophvsiological significance[J].Chinese Medical Journal,2007(5):421-426. 被引量:34
  • 2Aronson D.Hyperglycemia and the pathobiology of diabetic compli-cations[J].Adv Cardiol,2008,45(1):1-16.
  • 3Mehta JL,Li D.Identification,regulation and function of a novellectin-like ox-idized low-density lipoprotein receptor[J].J Am ColCardiol,2002,39(9):1 429.
  • 4Tang RN,Li Q,Lv LL,et al.Angiotensin II mediates the high-glucose-induced endothelial-to-mesenchymal transition in human aortic endothe-lial cells[J].Cardiovasc Diabetol,2010,9:31.
  • 5Yang XY,Jiang HG,Hartmann WK.Development of a quantitative an-tigen specific cell based ELISA for the 7G7/B6 monoclonal antibodydirected toward IL-2Ra[J].Immun Meth,2003,277(1):87-100.
  • 6Sawamura T,Kume N,Aoyama T,et al.A endothelial receptor for oxi-dized low density lipoprotein[J].Nature,1997,386(6620):73-77.
  • 7Novelli G,Mango R,Vecchione L,etal.New insights in atheroscle-rosis research:LOX-1,leading actor ofcardiovascular diseases[J].Clin Ter,2007,158:239-248.
  • 8Kataoka H,Kume N,Miyamoto S,et al.Expression of lectin-likeoxidized low-density lipoprotein receptor-1 in human atheroscleroticlesions[J].Circulation,1999,99:3 110-117.
  • 9Fukuhara-Takaki K,Sakai M,Sakai M,et al.Expression of class Ascavenger receptor is enhanced by high glucose in vitro and under dia-betic conditions invivo:one mechanism for an increased rate of athero-sclerosis in diabetes[J].J Biol Chem,2005,280(5):3 355-364.
  • 10Li L,Sawamura T,Renier G.Glucose enhances human macrophageLOX-1 expression:role for LOX-1 in glucose-induced macrophagefoam cell formation[J].Circ Res,2004,94(7):892-901.

共引文献14

同被引文献19

  • 1Savoia C,Burger D,Nishigaki N,et al. Angiotensin II and the vascular phenotype in hypertension[J]. Expert Rev Mol Med, 2011,13:el 1.
  • 2Zubcevic J, Waki H,Raizada MK,et aL Autonomic-immune-vascular interaction: an emerging concept for neurogenic hypertension[J]. Hypertension,2011,57(6):1026-33.
  • 3Versari D,Daghini E,Virdis A,et al. Endothelium-dependent contractions and endothelial dysfunction in human hypertension[J]. Br J Pharmacol, 2009,157(4):527-36.
  • 4Filip M,Maciag J,Nosalski R,et al. Endothelial dysfunction related to oxidative stress and inflammation in perivascular adipose tissue[J]. Postepy Biochem,2012,58(2): 186-94.
  • 5Sleight P. Clinical evidence from ONTARGET: the value of an angiotensin II receptor blocker and an angiotensin-converting enzyme inhibitor[J]. Hypertens Suppl,2009,27(5):23-9.
  • 6Tao X,Zhang SH,Chu ZX,et al. Apoptosis is involved in the cardiac damage induced by sinoaortic denervation in rats. Clin Exp Pharmacol Physiol,2003,30(5-6):362-8.
  • 7Fogati R,Malamani G,Zoppi A,et al. Effect on the development of ankle edema of adding delapril to manidipine in patipients with mild to modetate essential hypertension:a three-way crossover study[J]. Clin Ther,2007,29(3):413-8.
  • 8Bin Liu,Latika Dhawan,Burns C. Blaxall,Mark B.Taubman. Protein kinase C 8 mediates MCP-1 mRNA stabilization in vascular smooth muscle cells[J]. Molecular and Cellular Biochemistry. 2010 (1-2),344:73-9.
  • 9Yoshii T,Iwai M,Li Z,et al. Regression of atherosclerosis by amlodipine via anti-inflammatory and anti-oxidati[J]. Hypertens Res,2006,29(6):457-66.
  • 10Widdop RE,Vinh A,Henrion D,et al. Vascular angiotensin AT2 receptors in hypertension and ageing[J]. Clin Exp Phamacol Physiol,2008,35(9):386-90.

引证文献1

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部